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OBJECTIVE — To describe the clinical experience and the pharmacokinetics of U-500 reg-
ular insulin in severely insulin-resistant obese type 2 diabetic patients.
RESEARCH DESIGN AND METHODS — Patients requiring 200 units of insulin
withA1Clevels8.0%wereswitchedtoU-500regularinsulin.Forthepharmacokineticstudy,
fasting subjects received 100 units of U-500 regular insulin subcutaneously, and samples drawn
before and every 30–60 min for glucose, insulin, and C-peptides until glucose fell below 100
mg/dl.
RESULTS — U-500 regular insulin doses were adjusted using the same approach as for
adjusting NPH insulin doses. Mean values at baseline and at minimum A1C levels were, respec-
tively, A1C 9.9 and 7.1%, 3.2 and 3.3 units/kg, and weight 98.6 and 102.8 kg. Pharmacokineti-
cally, insulin concentrations rose briskly by 30 min and remained elevated for at least 7 h.
CONCLUSIONS — Uncontrolled severely insulin-resistant obese type 2 diabetic patients
can be satisfactorily controlled with U-500 regular insulin.
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C
linical or severe insulin resistance
(as opposed to pathophysiological
insulinresistance)isdeﬁnedasasit-
uation in which a patient requires 200
units of insulin daily. Obesity is by far the
most common cause. Patients with severe
insulinresistanceareverydifﬁculttotreat
successfully. More physicians are using
U-500 regular insulin to treat these pa-
tients (1,2). Although empirical observa-
tions suggest that this concentrated form
of regular insulin has a delayed time
course of action, there are no pharmaco-
kinetic studies representing its clinical
use. This article reports our experience
withall11ofourobesepatientsonU-500
regular insulin and its pharmacokinetics
in 9 of them.
RESEARCH DESIGN AND
METHODS— All patients treated with
U-500 regular insulin were taking 200
total units of U-100 NPH plus regular in-
sulin per day, had A1C levels 8.0% in
spite of working closely with our nurse
practitioners for at least 6 months, had
demonstrated willingness to self-measure
glucose concentrations at least twice a
day, and were able to understand the dif-
ferent dosing of U-500 regular insulin.
U-500 regular insulin doses were started
and changed according to a slight modi-
ﬁcation of a published algorithm (3).
Doses were adjusted to achieve 50% of
values before breakfast and supper be-
tween 70 and 130 mg/dl, as we typically
do with NPH insulin. Six patients had
A1C levels exceeding 7.5%, with pre-
prandial glucose concentrations in the
target range. Postprandial glucose con-
centrationsexceeded180mg/dlandwere
treated with preprandial U-100 lispro in-
sulin injected separately, aiming for a
postprandial target of 160 mg/dl.
To achieve a fasting plasma glucose
(FPG) concentration of 200 mg/dl on the
morning of the pharmacokinetic study, pa-
tients omitted their prior evening and that
morning’s insulin, increased their bedtime
snack the evening before, and arrived
fasting at the clinical research center.
One hundred units of U-500 regular in-
sulinwereinjectedsubcutaneously,and
plasma samples for glucose measured
immediately by a Yellow Springs Instru-
ment (YSI) were collected 10 min before,
just before, and every 30–60 min after
the injection until glucose concentrations
reached 100 mg/dl when the study was
stopped and the subject fed. Insulin and
C-peptide levels were measured by en-
zyme-linked immunosorbent assay. A1C
levels were measured every 3–4 months.
All patients were negative for insulin-
binding antibodies. The study was ap-
proved by the Charles Drew University
Institutional Review Board.
RESULTS— There were 10 female
subjects,10Latinosubjects,and1African
American subject. At baseline, their mean
duration of diabetes was 16.2 years, BMI
37.7 kg/m
2, weight 98.6 kg, total U-100
insulin dose 304 units (74% NPH), total
units/kg 3.2, and A1C level 9.9%. The
minimum (range) A1C achieved was
7.1% (6.0–7.4). A1C levels were 8.0%
in10of11patientsby3–4monthsandin
the11thpatientby6months.Theaverage
dose of insulin at the minimum A1C level
was 333 units, units/kg were 3.3, and
body weight was 102.8 kg. At the time
these data were collected, patients had
been followed for a mean of 26 months
after being switched to U-500 regular in-
sulin. The most recent A1C level was
7.5%(6.1–9.1),whichwasanaveragede-
crease of 2.4% (0.1 to 7.1).
In six patients who received lispro in-
sulin, the mean A1C level before the rap-
id-acting analog was introduced was
8.1%.Threeand6monthslater,itwas7.3
and 7.1%, respectively. Surprisingly, the
meanpreprandialdosewasonly9.5units
(6–15). Overall, episodes of hypoglyce-
mia (only one severe because of a missed
meal) seemed less than in our typical in-
sulin-requiring patients.
Insulin, C-peptide, and glucose con-
centrations are shown in Fig. 1. Glucose
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mg/dlfor3hinallninesubjects,for4hin
six,for5hinfour,for6hinthree,andfor
7 h in two. Insulin concentrations rose
briskly by 30 min and remained elevated
up to 7 h later. The increase in the mea-
suredlevelswasofexogenousoriginsince
C-peptide concentrations uniformly fell.
CONCLUSIONS — Substituting U-
500 regular insulin for U-100 NPH insu-
lin markedly improved diabetes control
in obese, severely insulin-resistant type 2
diabetic patients. Since these patients re-
ceived the same intensity of counseling
and insulin dose adjustments when they
were taking either U-100 NPH or U-500
regular insulin, their improved control
must have been due to the change in in-
sulin preparations. Although initially
there was rapid improvement in all pa-
tients and the minimum A1C levels
achieved were impressive (6.0–7.4%),
sustaining that improvement was chal-
lenging for some. All but one subject had
lower ﬁnal than initial A1C levels, but in
three subjects, ﬁnal values exceeded
8.0%.
The pharmacokinetic data in the ﬁg-
ure show that U-500 regular insulin has a
time course very similar to U-100 NPH
insulin(4).Althoughsomepatientsbegan
to meet the end point after 3 h and were
not sampled later, there is no reason to
believe that their insulin concentrations
would not have mirrored the patients
who continued to be sampled.
Three issues are often raised when
switchingtoU-500regularinsuliniscon-
sidered: the cost, patient confusion, and
which syringe to use. The more concen-
trated preparation is actually cheaper per
unit of insulin (1,5,6). Our experienced
certiﬁed diabetes educators must be com-
fortable with the patient’s ability to use
U-500regularinsulin.SinceweuseU-100
insulinsyringes(tuberculinsyringesarenot
easy to obtain; the needles are larger and
using the familiar “units” is less confusing),
we provide them with a conversion table
between the units of U-100 and U-500 in-
sulins. The written instructions to the pa-
tientandontheprescriptionstatetheactual
numberofunitsprescribedbutalsoinclude
in parentheses the number of syringe units
to which the U-500 insulin should be
drawn.
In conclusion, obese, severely insu-
lin-resistant, uncontrolled diabetic pa-
tients requiring 200 units/day can be
satisfactorily controlled on U-500 regular
insulin.Itrequiresacooperative,awarepa-
tient and frequent follow-up initially until
the dose is stabilized. Using it as one would
use NPH insulin is a simple approach that
worked well in this small cohort.
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